Jul 3, 2026 | Acquisition Cost Index (ACI) pricing, Biosimilars, Client Report, Drug costs, Formularies, MedBen Rx, Rx Costs, Specialty Drugs, Spending, Transparency
U.S. pharmaceutical expenditures rose 12.7% in 2025 to $915.2 billion, according to a recent analysis in the American Journal of Health-System Pharmacy. Utilization drove most of the growth, led by high-cost therapies such as tirzepatide, semaglutide, and apixaban....
Jun 22, 2026 | Acquisition Cost Index (ACI) pricing, MedBen Rx, Pharmacy Benefits Manager (PBM), Rebates, Spread Pricing
MedBen Rx is the fastest growing division of MedBen — and for good reason. Here’s how we stack up against traditional PBMs: CORE STRENGTHS OF MEDBEN RX OVER TRADITIONAL MODELS True Transparency & Pass-Through Traditional PBMs frequently use “spread...
Jan 12, 2026 | Acquisition Cost Index (ACI) pricing, Biosimilars, Brand Name Drugs, Drug costs, High-value formulary, MedBen Rx, News, Patient assistance, Pharmacogenomics, Pharmacy
Pharmaceutical manufacturers are planning to raise list prices on at least 350 brand-name medications in the United States beginning in 2026, up from 250 drugs last year, according to new data from health care research firm 3 Axis Advisors. These increases reflect...
Jan 5, 2024 | Access solutions, Acquisition Cost Index (ACI) pricing, Appropriateness Solutions, Benefits preservation, Comparative Effectiveness, Drug costs, MedBen Rx, Pricing solutions, Specialty Drugs
Pfizer, Sanofi, Takeda Pharmaceutical, and other drugmakers will raise the prices of more than 500 drugs in early January, according to an analysis by health care researchers 3 Axis Advisors. Inflation and rising manufacturing costs will contribute to the price...
Dec 22, 2023 | Acquisition Cost Index (ACI) pricing, Cost Plus Pricing, Cost Savings, Drug costs, MedBen Rx, Pharmacy, Prescription, Rx Costs, Savings, Spread Pricing
Spread pricing is the difference between what pharmacy benefit managers (PBMs) charge health plans for drugs and what the pharmacy actually pays for them. Often, this “spread” can be substantial, as PBMs profit greatly from their lack of transparency… so it’s not...
